Lake Street Private Wealth LLC Buys 776 Shares of Pfizer Inc. (NYSE:PFE)

Lake Street Private Wealth LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 8.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 10,096 shares of the biopharmaceutical company’s stock after acquiring an additional 776 shares during the quarter. Lake Street Private Wealth LLC’s holdings in Pfizer were worth $268,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Retirement Wealth Solutions LLC bought a new position in Pfizer during the 4th quarter valued at about $26,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the last quarter. Quarry LP acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the 3rd quarter valued at $35,000. Finally, Joseph Group Capital Management raised its position in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 771 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Down 0.7 %

Shares of NYSE:PFE opened at $26.30 on Friday. The company has a 50 day moving average price of $26.08 and a two-hundred day moving average price of $27.99. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $149.06 billion, a PE ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter last year, the business posted ($0.17) EPS. The firm’s revenue was up 31.2% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 227.03%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Guggenheim dropped their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Sanford C. Bernstein began coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.